References
- Castrejon I, Shum K, Tseng CE, Askanase A. Association between myasthaenia gravis and systemic lupus erythematosus: three case reports and review of the literature. Scand J Rheumatol 2011;40:486–90.
- Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 2011;23:444–8.
- Mu L, Sun B, Kong Q, Wang J, Wang G, Zhang S, Wang D, . Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009;128:e826–36.
- Roche JC, Capablo JL, Larrad L, Gervas-Arruga J, Ara JR, Sanchez A, . Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011;44:278–80.
- Ragheb S, Lisak R, Lewis R, Van Stavern G, Gonzales F, Simon K. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008;65:1358–62.
- Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, . Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10:778–85.